Sign in

You're signed outSign in or to get full access.

Thomas Saeli

Director at ULTRALIFE
Board

About Thomas L. Saeli

Thomas L. Saeli (age 68) has served as an independent director of Ultralife Corporation since March 2010. He is a former CEO, President, and director of JRB Enterprises / Duro-Last Inc. (2011–retired March 2024; sold to Holcim one year prior), previously CEO and director of Noble International, Ltd., and earlier VP of Corporate Development at Lear Corporation. He holds a BA in Economics (Hamilton College) and an MBA in Finance & Accounting (Columbia Business School) and is designated an “audit committee financial expert” under SEC rules .

Past Roles

OrganizationRoleTenureCommittees/Impact
JRB Enterprises / Duro-Last Inc.Chief Executive Officer, President, Director2011 – Mar 2024 (retired; company sold to Holcim in 2023)Led diversified manufacturer of low-slope commercial roofing systems
Consulting (international corporate clients)Consultant2009 – 2011Business development strategies, acquisitions, operations
Noble International, Ltd.Chief Executive Officer, DirectorNot specifiedInternational automotive supplier leadership
Lear CorporationVice President, Corporate DevelopmentNot specifiedCorporate development for global automotive supplier

External Roles

OrganizationRoleTenureNotes
Various privately held businesses and nonprofit organizationsDirector/Board MemberNot specifiedPrior service; specific entities not listed

Board Governance

  • Independence: Saeli is independent under NASDAQ rules for the Corporate Development & Governance Committee and the Compensation & Management Committee; he is also independent for the Audit & Finance Committee (CEO and the Board Chair are not independent for Audit) .
  • Committee leadership: Chair, Audit & Finance Committee; Member, Compensation & Management Committee; Member, Corporate Development & Governance Committee .
  • Attendance and engagement: Board held 5 meetings in 2024 and committees held 13; each director attended at least 75% of combined Board/committee meetings; all directors participated in last year’s annual meeting; independent directors held 4 executive sessions in 2024 .
  • Risk oversight: Audit & Finance oversees financial and cybersecurity risk; Corporate Development & Governance oversees enterprise risk management .
  • Retirement policy: Directors retire at the annual meeting following their 70th birthday (extends to 75 if >5% owner) .
CommitteeMembersChair2024 Meetings
Audit & FinanceThomas L. Saeli; Janie Goddard; Robert W. Shaw IIThomas L. Saeli4
Compensation & ManagementRobert W. Shaw II; Janie Goddard; Thomas L. SaeliRobert W. Shaw II4
Corporate Development & GovernanceJanie Goddard; Thomas L. Saeli; Robert W. Shaw IIJanie Goddard5

Fixed Compensation

ComponentAmountPeriod/Notes
Annual cash retainer (non-employee director)$73,500July 1, 2024 – June 30, 2025; prior period $70,040 (Jul 1, 2023 – Jun 30, 2024)
Committee chair retainer (Audit & Finance)$18,100July 1, 2024 – June 30, 2025; prior $17,250
Committee member retainer (Compensation & Management)$7,300July 1, 2024 – June 30, 2025; prior $6,950
Committee member retainer (Corporate Dev. & Governance)$7,300July 1, 2024 – June 30, 2025; prior $6,950
Director cash paid (FY 2024) – Saeli$102,443Earned in 2024; no other compensation elements

Program design note: Ultralife uses cash compensation and targets median director pay among like-sized/industry peers; retainers paid quarterly .

Performance Compensation

ComponentStatus
Stock awards (RSUs/PSUs)None granted to non-employee directors in 2024; none outstanding at 12/31/24
Option awardsNone granted to non-employee directors in 2024; none outstanding at 12/31/24
Non-equity incentive compensationNone for directors in 2024
Deferred compensation earningsNone for directors in 2024

Stock ownership guideline: Non-employee directors must hold at least $40,000 of ULBI stock (based on average purchase price per Form 4s); newly elected directors have two years to comply; all non-employee directors currently meet the guidelines .

Other Directorships & Interlocks

CategoryDetails
Current public company boardsNone disclosed for Saeli
Prior public company boardsCEO and director of Noble International, Ltd. (company status not specified in proxy)
Interlocks/conflictsNo compensation committee consultant conflicts disclosed; Compensation Committee has authority to retain outside experts

Expertise & Qualifications

  • Audit committee financial expert (SEC Item 407(d)(5)); financially literate under NASDAQ standards .
  • Manufacturing operations, corporate development, M&A, and finance experience; executive leadership at Duro-Last, Noble, Lear .
  • Education: BA Economics (Hamilton), MBA Finance & Accounting (Columbia Business School) .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingAs of
Thomas L. Saeli85,000<1%May 22, 2025

Policy notes:

  • Hedging/derivatives: Directors, officers, and employees are prohibited from short sales and from buying/selling options or other derivatives on Ultralife stock .
  • Related-party transactions: None reportable in 2024 or 2023; any related-party transactions must be reviewed by the Audit & Finance Committee .

Governance Assessment

  • Strengths
    • Independent director with deep operating and M&A experience; serves as Audit & Finance Committee Chair and designated audit committee financial expert, enhancing financial oversight and credibility of reporting and cybersecurity risk oversight .
    • Documented independence and strong engagement: at least 75% attendance threshold met; four independent executive sessions in 2024; all directors attended the last annual meeting .
    • Clear related-party oversight framework; no reportable related-party transactions in 2024/2023; hedging and derivative transactions prohibited, supporting alignment and risk discipline .
  • Watch items
    • Approaching retirement threshold: policy requires retirement following the 70th birthday (Saeli is 68), implying potential refresh/continuity considerations within 1–2 years .
    • Director compensation is cash-only with no recurring equity grants; while stock ownership guidelines are in place and met, the absence of annual equity awards may provide less direct long-term alignment than equity-centric programs at some peers .
    • Concentrated ownership by the non-independent Board Chair (37.4%) underscores the importance of robust independent committee leadership; Saeli’s audit chair role is a key counterbalance .

Notes

  • Committee meeting counts (2024): Board (5), Audit & Finance (4), Compensation & Management (4), Corporate Development & Governance (5) .
  • Auditor oversight: As Audit Chair, Saeli co-signed the committee’s report affirming auditor independence and recommending inclusion of audited financials in the 2024 Form 10-K .